Evidence map›Paper›PMID 39691825›Full record

ArticleFrontiers in chemistry2024

Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobe

Zhenghua Zhang, Yang Tian, Wenjun Gao, Yubin Hu, Liangping Luo, Lichang Lei, Shasha Shen, Dan Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhenghua Zhang *Medical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Yang Tian *Medical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Wenjun GaoMedical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Yubin HuMedical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Liangping LuoDepartment of Radiology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Lichang LeiMedical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Shasha ShenMedical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Dan HanMedical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Immune checkpoint inhibitors (ICIs) have demonstrated potential in inhibiting the growth of malignant pleural mesothelioma (MPM), and their efficacy is associated with the expression of programmed death-ligand 1(PD-L1). This study evaluated a PD-L1-targeted nanoprobe for detecting PD-L1 expression in a nude mouse model of malignant pleural mesothelioma (MPM). Methods: A PD-L1-binding peptide (WL-12) was conjugated with superparamagnetic iron oxide nanoparticles (SPIONs) to create the nanoprobe WL-12@Fe₃O₄. The nanoprobe's stability, biotoxicity, targeting ability, and Results: The WL-12@Fe₃O₄ nanoprobe demonstrated uniform distribution and a spherical shape, with a larger size (43.82 nm) and lower surface potential (-9.34 ± 0.54 mV) compared to Fe₃O₄ (32.67 nm, -20.20 ± 0.88 mV, Conclusion: The PD-L1-targeted nanoprobe with MRI is a promising tool for noninvasive, real-time assessment of PD-L1 expression in MPM.

Indexed as

immunotherapymagnetic resonance imaging (MRI)malignant pleural mesothelioma (MPM)nanoprobeprogrammed death ligand 1 (PD-L1)

Identifiers

PMID39691825
PMCPMC11650703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.